Aarti Drugs Assigned Strong ESG Rating of 'Crisil ESG 61' by Crisil
Aarti Drugs Limited received a 'Crisil ESG 61' (Strong) ESG rating from Crisil ESG Ratings based on FY 2025-26 data. The rating was independently assigned by Crisil and reported to the company on October 7, 2026.
An ESG rating, especially a strong one, can enhance the company's reputation and attractiveness to investors focused on sustainability, potentially impacting its valuation and access to capital.
The company has received a 'Strong' ESG rating, which is generally viewed positively by investors and stakeholders.
Aarti Drugs Limited has received an Environmental, Social, and Governance (ESG) Rating of ‘Crisil ESG 61’ (Strong) from Crisil ESG Ratings & Analytic Limited. The rating is based on data pertaining to the Financial Year 2025-26. The company was informed of this independent assessment via a report received on October 7, 2026. It is important to note that Aarti Drugs Limited had not engaged Crisil ESG Ratings for this rating; the report was prepared independently by Crisil ESG Ratings using publicly available data for FY 2025-26.
This disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and SEBI Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.